Biosimilars Treatment Market Report

Global Biosimilars Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 09, 2022
  • PAGES：213
  • REPORT CODE：GMM879242
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Biosimilars Treatment market report explains the definition, types, applications, major countries, and major players of the Biosimilars Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Biocon

    • Dr Reddy’s Laboratories

    • Samsung Bioepis

    • Amgen Inc

    • Sandoz International GmbH

    • Pfizer Inc

    • Roche Ltd

    • Celltrion Inc

    • Bayer

    • Eli Lily Inc

    • Teva Pharmaceutical Industries Limited

    By Type:

    • Recombinant Non – Glycosylated Proteins

    • Recombinant Glycosylated Proteins

    • Recombinant Peptides

    By End-User:

    • Oncology

    • Chronic and Autoimmune Disease

    • Blood Disorders

    • Growth Hormone Disease

    • Infectious Disease

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Biosimilars Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Biosimilars Treatment Outlook to 2028- Original Forecasts

    • 2.2 Biosimilars Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Biosimilars Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Biosimilars Treatment Market- Recent Developments

    • 6.1 Biosimilars Treatment Market News and Developments

    • 6.2 Biosimilars Treatment Market Deals Landscape

    7 Biosimilars Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Biosimilars Treatment Key Raw Materials

    • 7.2 Biosimilars Treatment Price Trend of Key Raw Materials

    • 7.3 Biosimilars Treatment Key Suppliers of Raw Materials

    • 7.4 Biosimilars Treatment Market Concentration Rate of Raw Materials

    • 7.5 Biosimilars Treatment Cost Structure Analysis

      • 7.5.1 Biosimilars Treatment Raw Materials Analysis

      • 7.5.2 Biosimilars Treatment Labor Cost Analysis

      • 7.5.3 Biosimilars Treatment Manufacturing Expenses Analysis

    8 Global Biosimilars Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Biosimilars Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Biosimilars Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Biosimilars Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Biosimilars Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Recombinant Non – Glycosylated Proteins Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Recombinant Glycosylated Proteins Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Recombinant Peptides Consumption and Growth Rate (2017-2022)

    • 9.2 Global Biosimilars Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Oncology Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Chronic and Autoimmune Disease Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Blood Disorders Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global Growth Hormone Disease Consumption and Growth Rate (2017-2022)

      • 9.2.5 Global Infectious Disease Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Biosimilars Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Biosimilars Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Biosimilars Treatment Consumption (2017-2022)

      • 10.2.2 Canada Biosimilars Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Biosimilars Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Biosimilars Treatment Consumption (2017-2022)

      • 10.3.2 UK Biosimilars Treatment Consumption (2017-2022)

      • 10.3.3 Spain Biosimilars Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Biosimilars Treatment Consumption (2017-2022)

      • 10.3.5 France Biosimilars Treatment Consumption (2017-2022)

      • 10.3.6 Italy Biosimilars Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Biosimilars Treatment Consumption (2017-2022)

      • 10.3.8 Finland Biosimilars Treatment Consumption (2017-2022)

      • 10.3.9 Norway Biosimilars Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Biosimilars Treatment Consumption (2017-2022)

      • 10.3.11 Poland Biosimilars Treatment Consumption (2017-2022)

      • 10.3.12 Russia Biosimilars Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Biosimilars Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Biosimilars Treatment Consumption (2017-2022)

      • 10.4.2 Japan Biosimilars Treatment Consumption (2017-2022)

      • 10.4.3 India Biosimilars Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Biosimilars Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Biosimilars Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Biosimilars Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Biosimilars Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Biosimilars Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Biosimilars Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Biosimilars Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Biosimilars Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Biosimilars Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Biosimilars Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Biosimilars Treatment Consumption (2017-2022)

      • 10.5.3 Chile Biosimilars Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Biosimilars Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Biosimilars Treatment Consumption (2017-2022)

      • 10.5.6 Peru Biosimilars Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Biosimilars Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Biosimilars Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Biosimilars Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Biosimilars Treatment Consumption (2017-2022)

      • 10.6.3 Oman Biosimilars Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Biosimilars Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Biosimilars Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Biosimilars Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Biosimilars Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Biosimilars Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Biosimilars Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Biosimilars Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Biosimilars Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Biosimilars Treatment Consumption (2017-2022)

    11 Global Biosimilars Treatment Competitive Analysis

    • 11.1 Biocon

      • 11.1.1 Biocon Company Details

      • 11.1.2 Biocon Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Biocon Biosimilars Treatment Main Business and Markets Served

      • 11.1.4 Biocon Biosimilars Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Dr Reddy’s Laboratories

      • 11.2.1 Dr Reddy’s Laboratories Company Details

      • 11.2.2 Dr Reddy’s Laboratories Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Dr Reddy’s Laboratories Biosimilars Treatment Main Business and Markets Served

      • 11.2.4 Dr Reddy’s Laboratories Biosimilars Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Samsung Bioepis

      • 11.3.1 Samsung Bioepis Company Details

      • 11.3.2 Samsung Bioepis Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Samsung Bioepis Biosimilars Treatment Main Business and Markets Served

      • 11.3.4 Samsung Bioepis Biosimilars Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Amgen Inc

      • 11.4.1 Amgen Inc Company Details

      • 11.4.2 Amgen Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Amgen Inc Biosimilars Treatment Main Business and Markets Served

      • 11.4.4 Amgen Inc Biosimilars Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Sandoz International GmbH

      • 11.5.1 Sandoz International GmbH Company Details

      • 11.5.2 Sandoz International GmbH Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Sandoz International GmbH Biosimilars Treatment Main Business and Markets Served

      • 11.5.4 Sandoz International GmbH Biosimilars Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Pfizer Inc

      • 11.6.1 Pfizer Inc Company Details

      • 11.6.2 Pfizer Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Pfizer Inc Biosimilars Treatment Main Business and Markets Served

      • 11.6.4 Pfizer Inc Biosimilars Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Roche Ltd

      • 11.7.1 Roche Ltd Company Details

      • 11.7.2 Roche Ltd Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Roche Ltd Biosimilars Treatment Main Business and Markets Served

      • 11.7.4 Roche Ltd Biosimilars Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Celltrion Inc

      • 11.8.1 Celltrion Inc Company Details

      • 11.8.2 Celltrion Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Celltrion Inc Biosimilars Treatment Main Business and Markets Served

      • 11.8.4 Celltrion Inc Biosimilars Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Bayer

      • 11.9.1 Bayer Company Details

      • 11.9.2 Bayer Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Bayer Biosimilars Treatment Main Business and Markets Served

      • 11.9.4 Bayer Biosimilars Treatment Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Eli Lily Inc

      • 11.10.1 Eli Lily Inc Company Details

      • 11.10.2 Eli Lily Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Eli Lily Inc Biosimilars Treatment Main Business and Markets Served

      • 11.10.4 Eli Lily Inc Biosimilars Treatment Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Teva Pharmaceutical Industries Limited

      • 11.11.1 Teva Pharmaceutical Industries Limited Company Details

      • 11.11.2 Teva Pharmaceutical Industries Limited Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Teva Pharmaceutical Industries Limited Biosimilars Treatment Main Business and Markets Served

      • 11.11.4 Teva Pharmaceutical Industries Limited Biosimilars Treatment Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    12 Global Biosimilars Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Biosimilars Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Recombinant Non – Glycosylated Proteins Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Recombinant Glycosylated Proteins Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Recombinant Peptides Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Biosimilars Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Oncology Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Chronic and Autoimmune Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Blood Disorders Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.4 Global Growth Hormone Disease Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.5 Global Infectious Disease Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Biosimilars Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Biosimilars Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Biosimilars Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Biosimilars Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Biosimilars Treatment

    • Figure of Biosimilars Treatment Picture

    • Table Global Biosimilars Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Biosimilars Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Recombinant Non – Glycosylated Proteins Consumption and Growth Rate (2017-2022)

    • Figure Global Recombinant Glycosylated Proteins Consumption and Growth Rate (2017-2022)

    • Figure Global Recombinant Peptides Consumption and Growth Rate (2017-2022)

    • Figure Global Oncology Consumption and Growth Rate (2017-2022)

    • Figure Global Chronic and Autoimmune Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Blood Disorders Consumption and Growth Rate (2017-2022)

    • Figure Global Growth Hormone Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Infectious Disease Consumption and Growth Rate (2017-2022)

    • Figure Global Biosimilars Treatment Consumption by Country (2017-2022)

    • Table North America Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure United States Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure Germany Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure China Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure Brazil Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Biosimilars Treatment Consumption by Country (2017-2022)

    • Figure Australia Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Biosimilars Treatment Consumption and Growth Rate (2017-2022)

    • Table Biocon Company Details

    • Table Biocon Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocon Biosimilars Treatment Main Business and Markets Served

    • Table Biocon Biosimilars Treatment Product Portfolio

    • Table Dr Reddy’s Laboratories Company Details

    • Table Dr Reddy’s Laboratories Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Dr Reddy’s Laboratories Biosimilars Treatment Main Business and Markets Served

    • Table Dr Reddy’s Laboratories Biosimilars Treatment Product Portfolio

    • Table Samsung Bioepis Company Details

    • Table Samsung Bioepis Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Samsung Bioepis Biosimilars Treatment Main Business and Markets Served

    • Table Samsung Bioepis Biosimilars Treatment Product Portfolio

    • Table Amgen Inc Company Details

    • Table Amgen Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Inc Biosimilars Treatment Main Business and Markets Served

    • Table Amgen Inc Biosimilars Treatment Product Portfolio

    • Table Sandoz International GmbH Company Details

    • Table Sandoz International GmbH Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sandoz International GmbH Biosimilars Treatment Main Business and Markets Served

    • Table Sandoz International GmbH Biosimilars Treatment Product Portfolio

    • Table Pfizer Inc Company Details

    • Table Pfizer Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Biosimilars Treatment Main Business and Markets Served

    • Table Pfizer Inc Biosimilars Treatment Product Portfolio

    • Table Roche Ltd Company Details

    • Table Roche Ltd Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Roche Ltd Biosimilars Treatment Main Business and Markets Served

    • Table Roche Ltd Biosimilars Treatment Product Portfolio

    • Table Celltrion Inc Company Details

    • Table Celltrion Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion Inc Biosimilars Treatment Main Business and Markets Served

    • Table Celltrion Inc Biosimilars Treatment Product Portfolio

    • Table Bayer Company Details

    • Table Bayer Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Biosimilars Treatment Main Business and Markets Served

    • Table Bayer Biosimilars Treatment Product Portfolio

    • Table Eli Lily Inc Company Details

    • Table Eli Lily Inc Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lily Inc Biosimilars Treatment Main Business and Markets Served

    • Table Eli Lily Inc Biosimilars Treatment Product Portfolio

    • Table Teva Pharmaceutical Industries Limited Company Details

    • Table Teva Pharmaceutical Industries Limited Biosimilars Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries Limited Biosimilars Treatment Main Business and Markets Served

    • Table Teva Pharmaceutical Industries Limited Biosimilars Treatment Product Portfolio

    • Figure Global Recombinant Non – Glycosylated Proteins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Recombinant Glycosylated Proteins Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Recombinant Peptides Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Oncology Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chronic and Autoimmune Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Blood Disorders Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Growth Hormone Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Infectious Disease Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Biosimilars Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Biosimilars Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US